EMBC vs PATH · P/E 12, rev $1.08B vs P/E 19, rev $1.61B
Embecta Corp (EMBC) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Embecta Corp (EMBC) is a medical instruments & supplies company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported EMBC revenue for 2025-09-30 was $1.08B. Net income was $95.4M. Revenue was down 3.8% from 2024-09-30 to 2025-09-30. EMBC currently screens at market cap $609.6M and trailing P/E 11.7.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
EMBC currently screens at market cap $609.6M and trailing P/E 11.7. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the EMBC and PATH stock pages for the full models.
Not investment advice.